Aveo Pharmaceuticals, Astellas deal

Astellas' OSI Pharmaceuticals Inc. subsidiary exercised an option for a non-exclusive license to use Aveo's Human Response Platform technology to identify epithelial-mesenchymal transition (EMT) agen...